KR102626672B1 - Composition comprising a Lactobacillus helveticus CKDB001 strain for the prevention, improvement, or treatment of alcoholic liver disease - Google Patents
Composition comprising a Lactobacillus helveticus CKDB001 strain for the prevention, improvement, or treatment of alcoholic liver disease Download PDFInfo
- Publication number
- KR102626672B1 KR102626672B1 KR1020220053421A KR20220053421A KR102626672B1 KR 102626672 B1 KR102626672 B1 KR 102626672B1 KR 1020220053421 A KR1020220053421 A KR 1020220053421A KR 20220053421 A KR20220053421 A KR 20220053421A KR 102626672 B1 KR102626672 B1 KR 102626672B1
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- liver disease
- present
- ckdb001
- composition
- Prior art date
Links
- 240000002605 Lactobacillus helveticus Species 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 235000013967 Lactobacillus helveticus Nutrition 0.000 title claims abstract description 16
- 229940054346 lactobacillus helveticus Drugs 0.000 title claims abstract description 16
- 208000022309 Alcoholic Liver disease Diseases 0.000 title claims description 41
- 230000002265 prevention Effects 0.000 title description 6
- 230000006872 improvement Effects 0.000 title description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 239000004480 active ingredient Substances 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- -1 Cxcl9 Proteins 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 5
- 101150031350 Cxcl2 gene Proteins 0.000 claims description 4
- 108010024212 E-Selectin Proteins 0.000 claims description 4
- 101100182723 Mus musculus Ly6g gene Proteins 0.000 claims description 4
- 102000015689 E-Selectin Human genes 0.000 claims 2
- 241001465754 Metazoa Species 0.000 description 17
- 208000019423 liver disease Diseases 0.000 description 16
- 230000036541 health Effects 0.000 description 13
- 239000003674 animal food additive Substances 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 230000037213 diet Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000013351 cheese Nutrition 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 244000005709 gut microbiome Species 0.000 description 5
- 231100000234 hepatic damage Toxicity 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000008818 liver damage Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000007863 steatosis Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010019133 Hangover Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000018191 liver inflammation Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000010827 pathological analysis Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 2
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000006749 inflammatory damage Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000004008 5'-Nucleotidase Human genes 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- CQAIPTBBCVQRMD-UHFFFAOYSA-L dipotassium;phosphono phosphate Chemical compound [K+].[K+].OP(O)(=O)OP([O-])([O-])=O CQAIPTBBCVQRMD-UHFFFAOYSA-L 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 235000011617 hard cheese Nutrition 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 락토바실러스 헬베티커스 (Lactobacillus helveticus) CKDB001 균주를 포함하는 조성물에 관한 것이다. The present invention relates to a composition containing Lactobacillus helveticus CKDB001 strain.
Description
본 발명은 락토바실러스 헬베티커스 (Lactobacillus helveticus) CKDB001 균주를 포함하는 조성물에 관한 것으로, 보다 자세하게는 상기 균주를 유효성분으로 포함하여 알코올성 간질환 (Alcoholic liver disease, ALD) 억제 효과 및 장내 미생물 조절을 통한 이로운 효과를 얻기 위해 사용될 수 있는 L. helveticus CKDB001 균주에 관한 것으로 이 균주를 사용해 알코올성 간질환 유도 마우스에서 알코올성 지방간 또는 알코올성 간염 억제 및 장내 미생물 조절을 통한 알코올성 간질환에 이로운 효과를 얻는 방법에 관한 것이다.The present invention relates to Lactobacillus helveticus It relates to a composition containing the CKDB001 strain, and more specifically, L. helveticus , which contains the strain as an active ingredient and can be used to obtain beneficial effects through suppressing alcoholic liver disease (ALD) and regulating intestinal microorganisms. This relates to the CKDB001 strain and how to use this strain to obtain beneficial effects on alcoholic liver disease by suppressing alcoholic fatty liver disease or alcoholic hepatitis and controlling intestinal microorganisms in mice induced with alcoholic liver disease.
알코올 및 알코올과 함께 섭취하는 고칼로리 식품 섭취는 비만 및 간질환의 발생을 증가시키고 있다. 알코올은 여러 말단 기관, 주로 간, 장 및 뇌에 손상을 일으킨다. 그러나 알코올 또는 알코올 관련 손상으로 인한 말단 기관 손상의 발병은 매우 개별적이며 예측할 수 없다. 알코올성 간질환은 만성간질환으로, 전세계적으로 발생되는 간질환에 의한 사망률의 주요 원인 중 하나이다. 알코올 오남용으로 인한 환자의 약 20~30%는 간 손상을 일으키고 그보다 더 적은 수는 간경화 또는 알코올성 간염을 일으킨다. 따라서, 알코올성 간질환은 알코올성 지방간으로부터 지방간염, 간섬유증, 간경변증 등으로 진행될 수 있으며 더 심한 경우에는 간암으로도 이어지는 질환이다. [Bajaj, J.S. Alcohol, liver disease and the gut microbiota. Nature Reviews Gastroenterology & Hepatology 2019, 16, 235-246.]Consumption of alcohol and high-calorie foods combined with alcohol increases the incidence of obesity and liver disease. Alcohol causes damage to several end organs, primarily the liver, intestines, and brain. However, the onset of end-organ damage due to alcohol or alcohol-related injury is highly individualized and unpredictable. Alcoholic liver disease is a chronic liver disease and is one of the main causes of mortality due to liver disease worldwide. About 20-30% of patients who misuse alcohol develop liver damage, and a smaller number develop cirrhosis or alcoholic hepatitis. Therefore, alcoholic liver disease can progress from alcoholic fatty liver to steatohepatitis, liver fibrosis, cirrhosis, etc., and in more severe cases, it can even lead to liver cancer. [Bajaj, J.S. Alcohol, liver disease and the gut microbiota. Nature Reviews Gastroenterology & Hepatology 2019, 16, 235-246.]
알코올 섭취로 인한 장내 미생물 구성의 변화는 알코올성 간질환의 발병 및 진행에 영향을 줄 수 있고 질병이 진행됨에 따라 악화될 수 있다. [Seitz, H.K.; Bataller, R.; Cortez-Pinto, H.; Gao, B.; Gual, A.; Lackner, C.; Mathurin, P.; Mueller, S.; Szabo, G.; Tsukamoto, H. Alcoholic liver disease. Nature Reviews Disease Primers 2018, 4, 1-22.]Changes in gut microbiota composition due to alcohol consumption may influence the onset and progression of alcoholic liver disease and may worsen as the disease progresses. [Seitz, H.K.; Bataller, R.; Cortez-Pinto, H.; Gao, B.; Gual, A.; Lackner, C.; Mathurin, P.; Mueller, S.; Szabo, G.; Tsukamoto, H. Alcoholic liver disease. Nature Reviews Disease Primers 2018, 4, 1-22.]
한편, 인체에는 약 100조 개의 미생물이 존재하는 것으로 알려져 있다. 인간의 신체에 공생하는 모든 미생물과 이들의 유전정보를 총칭하여 휴먼 마이크로바이옴 (Human microbiome)이라고 하고 각 조직 및 기관은 고유한 생리 기능을 가지고 있기 때문에 서로 다른 다양한 미생물총과 화학적 환경이 존재한다. 인체에는 장에 가장 많은 공생 미생물이 서식하고 있는 것으로 알려져 있다. [Bruzzese, E.; Volpicelli, M.; Squaglia, M.; Tartaglione, A.; Guarino, A. Impact of prebiotics on human health. Digestive and Liver Disease 2006, 38, S283-S287.] [Valdes, A.M.; Walter, J.; Segal, E.; Spector, T.D. Role of the gut microbiota in nutrition and health. Bmj 2018, 361.] Meanwhile, it is known that about 100 trillion microorganisms exist in the human body. All microorganisms that coexist in the human body and their genetic information are collectively referred to as the human microbiome. Since each tissue and organ has its own unique physiological function, a variety of different microflora and chemical environments exist. . It is known that the largest number of symbiotic microorganisms live in the intestines of the human body. [Bruzzese, E.; Volpicelli, M.; Squaglia, M.; Tartaglione, A.; Guarino, A. Impact of prebiotics on human health. Digestive and Liver Disease 2006, 38, S283-S287.] [Valdes, A.M.; Walter, J.; Segal, E.; Spector, T.D. Role of the gut microbiota in nutrition and health. Bmj 2018, 361.]
모든 장내 미생물의 약 99%는 유산균과 비피더스균을 포함한 공생 박테리아로 존재한다. 이들은 영양소 처리 및 신호 전달에 기여하고 비타민 및 단쇄지방산 (Short chain fatty acids, SCFAs)과 같은 필수 기능을 가진 대사 산물을 생산한다. 적당량을 섭취했을 때 인체에 이로움을 주는 살아있는 균을 프로바이오틱스 (Probiotics) 라고 정의하는데 프로바이오틱스는 대사질환, 장관질환, 알러지성 질환, 호흡기 감염증, 간질환, 기타 질환 등을 개선하는 효능을 가지고 있다. 특히, 비알코올성 지방간질환 (Non-alcoholic fatty liver disease, NAFLD)의 인슐린저항성 개선과 간지방증을 감소시킨다고 알려져 있으나 현재까지 알코올성 간질환에서의 프로바이오틱스 효능은 미미하게 알려져 있으며 이를 통해 발생하는 메커니즘을 완전히 규명하기 위해서는 광범위한 연구가 요구된다.Approximately 99% of all intestinal microorganisms exist as commensal bacteria, including lactic acid bacteria and bifidobacteria. They contribute to nutrient processing and signal transduction and produce metabolites with essential functions such as vitamins and short chain fatty acids (SCFAs). Probiotics are defined as live bacteria that are beneficial to the human body when consumed in appropriate amounts. Probiotics have the effect of improving metabolic diseases, intestinal diseases, allergic diseases, respiratory infections, liver diseases, and other diseases. In particular, it is known to improve insulin resistance and reduce hepatic steatosis in non-alcoholic fatty liver disease (NAFLD), but to date, the efficacy of probiotics in alcoholic liver disease is poorly known, and the mechanism through which this occurs has not been fully identified. To do this, extensive research is required.
L. helveticus는 Lactobacillus 속의 한 종으로 발효유 음료 및 일부 유형의 경질 치즈 생산에 가장 일반적으로 사용되는 유산균이며 그람 양성 유산균이다. L. helveticus는 수송 시스템 및 세포 내 펩티다제로 구성된 고효율 단백질 분해 시스템을 보유하고 있으며, 치즈 가공에 L. helveticus를 사용하는 것 외에도 건강 증진 특성을 지닌 발효유 제조에 산업적으로 응용되고 있다. [Griffiths, M.W.; Tellez, A.M. Lactobacillus helveticus: the proteolytic system. Front Microbiol 2013, 4, 30, doi:10.3389/fmicb.2013.00030.] 선행 연구에 따르면 발효 유제품은 혈압을 낮추고 면역 체계를 자극하며 칼슘 흡수를 촉진하고 병원체에 대한 항독성 효과를 발휘할 수 있다. 이러한 유익한 효과는 L. helveticus의 단백질 분해 시스템에 의해 우유 단백질이 가수분해되는 동안 방출되는 다양한 펩타이드에 의해 생성되며, 이는 박테리아에게 성장을 위해 요구되는 영양분을 제공한다는 연구결과도 있다. 하지만 알코올성 간질환의 예방 및 치료에 대한 연구가 부족하여 알코올성 간질환의 개선이나 치료에 필요한 L. helveticus의 효능 및 기능성 규명이 필요하다. L. helveticus is a species of the genus Lactobacillus , a gram-positive lactic acid bacterium most commonly used in the production of fermented milk beverages and some types of hard cheese. L. helveticus possesses a highly efficient proteolytic system consisting of a transport system and intracellular peptidases, and in addition to using L. helveticus in cheese processing, it has industrial applications in the production of fermented milk with health-promoting properties. [Griffiths, M.W.; Tellez, AM Lactobacillus helveticus: the proteolytic system. Front Microbiol 2013, 4, 30, doi:10.3389/fmicb.2013.00030.] Previous studies have shown that fermented dairy products can lower blood pressure, stimulate the immune system, promote calcium absorption, and exert anti-toxic effects on pathogens. Studies have shown that this beneficial effect is produced by various peptides released during the hydrolysis of milk proteins by the proteolytic system of L. helveticus , which provides the bacteria with the nutrients required for growth. However, due to a lack of research on the prevention and treatment of alcoholic liver disease, it is necessary to identify the efficacy and functionality of L. helveticus for the improvement or treatment of alcoholic liver disease.
본 발명에서는 리코타치즈 (홈메이드)에서 분리한 L. helveticus CKDB001 균주를 사용하였다. 알코올성 간질환 유도 마우스 모델에서 L. helveticus CKDB001 균주의 섭취로 인해 장내 미생물총이 조절되어 알코올성 간질환을 개선시킴을 확인하였다.In the present invention, the L. helveticus CKDB001 strain isolated from ricotta cheese (homemade) was used. In an alcoholic liver disease-induced mouse model, it was confirmed that consumption of L. helveticus CKDB001 strain improved alcoholic liver disease by regulating the intestinal microflora.
본 발명의 목적은 L. helveticus CKDB001 균주가 알코올성 간질환을 개선하고 장내 미생물총 조절을 통한 지방 생성 인자 감소와 면역 증진 효과가 있어 상기 균주를 포함하는 생균제를 알코올성 간질환 예방 및 치료용 조성물로 제안함에 있다.The purpose of the present invention is that the L. helveticus CKDB001 strain improves alcoholic liver disease and has the effect of reducing fat production factors and improving immunity through regulating intestinal microflora, so a probiotic containing the strain is proposed as a composition for preventing and treating alcoholic liver disease. It is in doing.
또한, 본 발명이 해결하고자 하는 과제들은 이상에서 언급된 과제로 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 통상의 기술자에게 명확하게 이해될 수 있을 것이다.In addition, the problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.
상기와 같은 목적을 달성하기 위하여 본 발명의 일 실시예에 따르면, 본 발명은 리코타치즈 (홈메이드)에서 분리된 L. helveticus CKDB001 균주를 제공할 수 있고, 상기 균주는 알코올성 간질환에 대한 예방과 치료에 이용될 수 있다.In order to achieve the above object, according to an embodiment of the present invention, the present invention can provide an L. helveticus CKDB001 strain isolated from ricotta cheese (homemade), and the strain is used to prevent alcoholic liver disease. It can be used for treatment.
본 발명의 다른 실시예에 따르면, 수탁번호 KCTC 13670BP인 락토바실러스 헬베티커스 CKDB001 균주를 유효성분으로 포함하는 간질환의 예방 또는 치료용 약학적 조성물을 제공한다.According to another embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating liver disease containing Lactobacillus helveticus CKDB001 strain, accession number KCTC 13670BP, as an active ingredient.
또한 본 발명에서, 상기 균주는 1x108 CFU/g 이상인 것일 수 있다.Also, in the present invention, the strain may be 1x10 8 CFU/g or more.
또한 본 발명에서, 상기 간질환은 알코올 섭취로 인한 것일 수 있다.Additionally, in the present invention, the liver disease may be caused by alcohol consumption.
또한 본 발명에서, 상기 간질환은 염증성 간질환인 것일 수 있다.Additionally, in the present invention, the liver disease may be an inflammatory liver disease.
본 발명의 또 다른 실시예에 따르면, 수탁번호 KCTC 13670BP인 락토바실러스 헬베티커스 CKDB001 균주를 유효성분으로 포함하는 간기능 개선용 식품 조성물을 제공하는 것일 수 있다.According to another embodiment of the present invention, a food composition for improving liver function containing the Lactobacillus helveticus CKDB001 strain, accession number KCTC 13670BP, as an active ingredient may be provided.
본 발명의 또 다른 실시예에 따르면, 수탁번호 KCTC 13670BP인 락토바실러스 헬베티커스 CKDB001 균주를 유효성분으로 포함하는 숙취해소용 조성물을 제공하는 것일 수 있다.According to another embodiment of the present invention, a composition for relieving a hangover containing Lactobacillus helveticus CKDB001 strain, accession number KCTC 13670BP, as an active ingredient may be provided.
상기와 같은 본 발명에 따르면, 리코타치즈 (홈메이드)에서 분리된 L. helveticus CKDB001 균주를 제공하는 효과가 있다. 또한, 본 발명에 따른 L. helveticus CKDB001 균주를 알코올성 간질환 유도 마우스에 투여하였을 경우 간 조직에서 지방과 염증 생성 유전자의 발현을 저하시키고 병리학적으로도 지방간과 염증으로부터 보호 및 억제시키는 효과를 가지므로 알코올성 간질환에 대한 예방과 치료에 이용될 수 있다.According to the present invention as described above, there is an effect of providing the L. helveticus CKDB001 strain isolated from ricotta cheese (homemade). In addition, when the L. helveticus CKDB001 strain according to the present invention is administered to mice induced with alcoholic liver disease, it reduces the expression of genes producing fat and inflammation in liver tissue and has the effect of protecting and suppressing pathological fatty liver and inflammation. It can be used to prevent and treat alcoholic liver disease.
도 1은 에탄올 포함 식이 섭취로 유도한 알코올성 간질환 마우스 모델 모식도를 나타낸 것이다.
도 2는 알코올성 간질환 유도 마우스 모델에서 L. helveticus CKDB001 균주의 간 조직을 확인한 결과, 알코올성 간질환 억제 효과를 확인한 것이다.
도 3은 알코올성 간질환 유도 마우스의 혈액에서 L. helveticus CKDB001 균주의 간기능 지표 비교도를 나타낸 것이다.
도 4는 알코올성 간질환 유도 마우스의 간에서 L. helveticus CKDB001 균주의 염증성 사이토카인 및 케모카인 유전자 발현 억제 측정도를 나타낸 것이다.Figure 1 shows a schematic diagram of an alcoholic liver disease mouse model induced by dietary intake containing ethanol.
Figure 2 shows the liver tissue of the L. helveticus CKDB001 strain in an alcoholic liver disease-induced mouse model, confirming the effect of suppressing alcoholic liver disease.
Figure 3 shows a comparison of liver function indicators of L. helveticus CKDB001 strain in the blood of mice induced with alcoholic liver disease.
Figure 4 shows the measurement of inhibition of inflammatory cytokine and chemokine gene expression of L. helveticus CKDB001 strain in the liver of mice induced with alcoholic liver disease.
이하, 본 발명에 대하여 상세히 설명하기로 한다. 이에 앞서, 본 명세서 및 특허청구범위에 사용된 용어 또는 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다. 따라서, 본 명세서에 기재된 실시예에 기재된 구성은 본 발명의 가장 바람직한 일 실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.Hereinafter, the present invention will be described in detail. Prior to this, the terms or words used in this specification and patent claims should not be construed as limited to their usual or dictionary meanings, and the inventor must appropriately use the concept of the term to explain his or her invention in the best way. It must be interpreted as meaning and concept consistent with the technical idea of the present invention based on the principle that it can be defined clearly. Accordingly, the configuration described in the embodiments described in this specification is only one of the most preferred embodiments of the present invention and does not represent the entire technical idea of the present invention, so at the time of filing this application, various equivalents and It should be understood that variations may exist.
한편, 본 명세서에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시 형태에도 적용될 수 있다. 즉, 본 명세서에서 개시된 다양한 요소들의 모든 조합이 본 출원의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.
Meanwhile, each description and embodiment disclosed in this specification may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein fall within the scope of the present application. Additionally, the scope of the present invention cannot be considered limited by the specific description described below.
본 발명의 조성물이 포함하는 균주인 “락토바실러스 헬베티커스 (Lactobacillus helveticus)”는 혐기성이고 운동성이 없는 그람 양성 간균으로, 락토바실러스 (Lactobacillus) 속에 속하는 것으로 알려져 있다.“ Lactobacillus helveticus ,” a strain included in the composition of the present invention, is an anaerobic, non-motile Gram-positive bacillus and is known to belong to the genus Lactobacillus .
본 발명의 락토바실러스 헬베티커스 (Lactobacillus helveticus) CKDB001 균주는 "한국생명공학연구원 미생물자원센터 (Korean Collection for Type Culture; KCTC)"에 수탁번호 KCTC 13670BP로 기탁된 것이고, 서열번호 2로 표시되는 16s rRNA 염기서열을 포함하는 것일 수 있다.The Lactobacillus helveticus CKDB001 strain of the present invention was deposited at the "Korean Collection for Type Culture (KCTC)" of the Korea Research Institute of Bioscience and Biotechnology under the accession number KCTC 13670BP, and has 16s represented by SEQ ID NO: 2. It may contain an rRNA base sequence.
본 발명에서, 상기 균주는 분말의 생균제 형태로 포함된 것일 수 있다. 보다 구체적으로 상기 균주의 농도는 1x108 CFU/g 이상인 것일 수 있고, 바람직하게는 1x109 CFU/g 인 것일 수 있다. 상기 농도 이상의 균주를 포함한 경우, 섭취하였을 때 체내에서 장내 마이크로바이옴을 변화시키기에 충분할 수 있다.In the present invention, the strain may be included in the form of a powdered probiotic. More specifically, the concentration of the strain may be 1x10 8 CFU/g or more, preferably 1x10 9 CFU/g. If the strain exceeds the above concentration, it may be sufficient to change the intestinal microbiome in the body when ingested.
본 발명의 유효성분인 상기 균주는, 상기 균주를 분리 및/또는 정제한 균체 외에 균체를 포함하는 배양물, 균체의 추출물, 배양물 상층액, 이들의 농축액, 농축물, 건조물 또한 필요에 따라서 희석액, 희석물 등이며, 배양액, 배양물을 처리하여 얻어지는 모든 상태의 것을 포함할 수 있다.The strain, which is an active ingredient of the present invention, includes, in addition to the bacterial cells isolated and/or purified, cultures containing the bacterial cells, extracts of the bacterial cells, culture supernatants, concentrates, concentrates, dried products thereof, and, if necessary, diluted solutions. , dilutions, etc., and may include culture medium and any state obtained by processing the culture.
본 발명에서, 상기 균주의 균체에 대한 배양법, 추출법, 분리법, 농축법, 건조법, 희석법 등은 특별히 한정되지 않는다. 상기 균체를 배양하기 위한 배지로는 EG 배지; LB 배지; RCM 배지; 및/또는 혈소판 (blood plate), 말토오즈 (maltose), 수크로오즈 (sucrose), 글루코오즈 (glucose), 녹말 (starch), 만니톨 (mannitol), 젤라틴 (gelatin), 카제인 (casein), 스킴밀크 (skim milk), 그 밖의 당류 및 효모 추출물에서 선택된 어느 하나 이상의 성분을 포함하는 배지;일 수 있으며, 배양 방법으로는 일반적인 각종 호기적 또는 혐기적인 방법을 사용할 수 있고, 상기 균주의 배양 온도로는 30℃내지 40℃를 설정하고, 배양 중에는 수산화나트륨 등의 알칼리를 사용하여 배지의 pH를 중성으로부터 산성, 예를 들어 pH가 5 내지 6 정도가 되도록 유지하는 중화배양법을 사용할 수도 있다. 이와 같은 중화배양법 외에 회분배양법 등의 임의의 배양 방법을 사용할 수 있으며, 배양한 후에는 필요에 따라서 배양물이나 그 상층액을 농축, 건조, 희석 등을 할 수도 있다. 또한 원심분리법이나 막분리법을 사용하여 배양물의 상층액과 균체를 분리하여 균체를 농축한 상태로 회수할 수도 있다. 그리고 균체에 초음파 처리나 효소 처리 등을 행하여 균체 내의 성분을 추출하거나, 배양물이나 그 상층액, 균체나 그 추출물 등을 건조할 수도 있다. 이들은 본 발명의 상기 조성물의 유효성분으로서 사용할 수 있다.In the present invention, the cultivation method, extraction method, separation method, concentration method, drying method, dilution method, etc. for the cells of the above strain are not particularly limited. The medium for culturing the bacterial cells includes EG medium; LB medium; RCM badge; and/or blood plate, maltose, sucrose, glucose, starch, mannitol, gelatin, casein, skim milk. (skim milk), other sugars, and yeast extract; may be a medium containing one or more components selected from the group consisting of A neutralization culture method may be used in which the temperature is set at 30°C to 40°C and an alkali such as sodium hydroxide is used during the culture to maintain the pH of the medium from neutral to acidic, for example, pH around 5 to 6. In addition to this neutralization culture method, any culture method such as batch culture can be used, and after culture, the culture or its supernatant can be concentrated, dried, diluted, etc., as needed. Additionally, the supernatant of the culture and the bacterial cells can be separated using centrifugation or membrane separation, and the bacterial cells can be recovered in a concentrated state. In addition, the bacterial cells can be subjected to ultrasonic treatment or enzyme treatment to extract components within the bacterial cells, or the culture, its supernatant, the bacterial cells or their extracts, etc. can be dried. These can be used as active ingredients in the composition of the present invention.
본 발명의 상기 "예방"이란, 본 발명의 상기 조성물을 이용하여 알코올성 간질환에 의해 발생되는 증상을 차단하거나, 그 증상을 억제 또는 지연시키는 행위라면 제한 없이 포함될 수 있다.The "prevention" of the present invention may include without limitation any act of blocking, suppressing or delaying symptoms caused by alcoholic liver disease using the composition of the present invention.
본 발명의 상기 "치료"란, 본 발명의 상기 조성물을 이용하여 알코올성 간질환에 의해 발생된 증상이 호전되거나 이롭게 되는 행위라면 제한 없이 포함될 수 있다.The term “treatment” of the present invention may be included without limitation as long as it is an act of improving or benefiting symptoms caused by alcoholic liver disease using the composition of the present invention.
본 발명의 상기 "개선"이란, 본 발명의 상기 조성물을 이용하여 알코올성 간질환에 의해 발생되는 증상이 호전되거나 이롭게 되는 모든 행위라면 제한 없이 포함될 수 있다.
The "improvement" of the present invention may include without limitation any action that improves or benefits symptoms caused by alcoholic liver disease by using the composition of the present invention.
본 발명의 일 구현예에 따르면, 수탁번호 KCTC 13670BP인 락토바실러스 헬베티커스 CKDB001 균주를 유효성분으로 포함하는 간질환의 예방 또는 치료용 약학적 조성물을 제공한다.According to one embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating liver disease containing Lactobacillus helveticus CKDB001 strain, accession number KCTC 13670BP, as an active ingredient.
본 발명에서, 상기 균주는 1x108 CFU/g 이상 농도인 것일 수 있고, 바람직하게는 1x108 CFU/g 이상 농도인 것일 수 있다.In the present invention, the strain may have a concentration of 1x10 8 CFU/g or more, and preferably may have a concentration of 1x10 8 CFU/g or more.
본 발명에서, 상기 간질환은 알코올 섭취로 인한 것일 수 있다.In the present invention, the liver disease may be caused by alcohol consumption.
본 발명에서, 상기 간질환은 염증성 간질환인 것일 수 있다. 본 발명의 상기 염증성 간질환은 간경변 (cirrhosis), C형 간염, 알코올성 간질환, 진행성 섬유증으로 인한 간 손상, 간 섬유증, 원발성 담즙성 간경변 (PBC) 및 원발성 경화성 담관염 (PSC)에서 선택된 어느 하나 이상이 질환을 동반한 간 염증이 포함될 수 있고, 간 염증의 예방, 치료 또는 개선으로 인한 빌리루빈, 및/또는 간 효소, 예컨대 알칼리성 포스파타제 (ALP, AP, 또는 Alk Phos), 알라닌 아미노트랜스퍼라제 (ALT), 아스파르테이트 아미노트랜스퍼라제 (AST), 감마-글루타밀 트랜스펩티다제 (GGT), 락테이트 데하이드로게나제 (LDH) 및 5' 뉴클레오티다제의 감소를 기대할 수 있다.In the present invention, the liver disease may be an inflammatory liver disease. The inflammatory liver disease of the present invention includes at least one selected from cirrhosis, hepatitis C, alcoholic liver disease, liver damage due to progressive fibrosis, liver fibrosis, primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Liver inflammation accompanying this disease may include bilirubin, and/or liver enzymes such as alkaline phosphatase (ALP, AP, or Alk Phos), alanine aminotransferase (ALT) due to the prevention, treatment, or amelioration of liver inflammation. , a reduction in aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH) and 5' nucleotidase can be expected.
본 발명의 상기 약학적 조성물은 이들로 한정되는 것은 아니지만, 각각 통상의 방법에 따라 산제, 과립제, 캡슐, 정제, 수성 현탁액 등의 경구형 제형, 외용제, 좌제 및 멸균 주사 용액의 형태로 제형화하여 사용될 수 있다. The pharmaceutical composition of the present invention is not limited to these, but is formulated into oral dosage forms such as powders, granules, capsules, tablets, and aqueous suspensions, external preparations, suppositories, and sterile injection solutions according to conventional methods. can be used
본 발명의 상기 약학적 조성물은 약학적으로 허용 가능한 담체를 포함할 수 있다. 상기 약학적으로 허용되는 담체는 경구 투여 시에는 결합제, 활탁제, 붕해제, 부형제, 가용화제, 분산제, 안정화제, 현탁화제, 색소, 향료 등을 사용할 수 있고, 주사제의 경우에는 완충제, 보존제, 무통화제, 가용화제, 등장제, 안정화제 등을 혼합하여 사용할 수 있으며, 국소투여용의 경우에는 기제, 부형제, 윤활제, 보존제 등을 사용할 수 있다.The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, colorants, flavorings, etc. for oral administration, and for injections, buffers, preservatives, Analgesics, solubilizers, isotonic agents, stabilizers, etc. can be mixed and used, and for topical administration, bases, excipients, lubricants, preservatives, etc. can be used.
본 발명의 상기 약학적 조성물의 제형은 상술한 바와 같은 약학적으로 허용되는 담체와 혼합하여 다양하게 제조될 수 있다. 예를 들어, 경구 투여시에는 정제, 트로키, 캡슐, 엘릭서 (Elixir), 서스펜션, 시럽, 웨이퍼 등의 형태로 제조할 수 있으며, 주사제의 경우에는 단위 투약 앰플 또는 다수 회 투약 형태로 제조할 수 있다. 기타, 용액, 현탁액, 정제, 캡슐, 서방형 제제 등으로 제형화 할 수 있다.The formulation of the pharmaceutical composition of the present invention can be prepared in various ways by mixing it with a pharmaceutically acceptable carrier as described above. For example, for oral administration, it can be manufactured in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, it can be manufactured in the form of unit dose ampoules or multiple doses. there is. In addition, it can be formulated into solutions, suspensions, tablets, capsules, sustained-release preparations, etc.
본 발명의 상기 제제화에 적합한 담체, 부형제 및 희석제의 예로는, 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말디톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 또는 광물유 등이 사용될 수 있다. 또한, 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 포함할 수 있다.Examples of carriers, excipients and diluents suitable for the formulation of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium. Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil may be used. In addition, fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives, etc. may be additionally included.
본 발명의 상기 약학적 조성물의 투여 경로는 이들로 한정되는 것은 아니지만 구강, 정맥내, 근육내, 동맥내, 골수내, 경막내, 심장내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장이 포함된다. 경구 또는 투하가 바람직하다. 본 발명에서 상기 "비경구"는 피하, 피내, 정맥내, 근육내, 관절내, 활액낭내, 흉골내, 경막내, 병소내 및 두개골내 주사 또는 주입 기술을 포함한다.The route of administration of the pharmaceutical composition of the present invention is not limited to these, but is oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, and topical. , sublingual or rectal. Oral or intravenous administration is preferred. In the present invention, the term “parenteral” includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
본 발명의 상기 약학적 조성물은 사용된 특정 화합물의 활성, 연령, 체중, 일반적인 건강, 성별, 정식, 투여 시간, 투여 경로, 배출율, 약물 배합 및 예방 또는 치료될 특정 질환의 중증을 포함한 여러 요인에 따라 다양하게 변할 수 있고, 상기 약학적 조성물의 투여량은 환자의 상태, 체중, 질병의 정도, 약물 형태, 투여 경로 및 기간에 따라 다르지만 당업자에 의해 적절하게 선택될 수 있고, 1일 0.0001 내지 50 mg/kg 또는 0.001 내지 50 mg/kg으로 투여할 수 있다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. 본 발명에 따른 약학적 조성물은 환제, 당의정, 캡슐, 액제, 겔, 시럽, 슬러리, 현탁제로 제형화될 수 있다.
The pharmaceutical composition of the present invention depends on several factors, including the activity of the specific compound used, age, body weight, general health, gender, diet, administration time, administration route, excretion rate, drug formulation, and the severity of the specific disease to be prevented or treated. The dosage of the pharmaceutical composition may vary depending on the patient's condition, weight, degree of disease, drug form, administration route and period, but may be appropriately selected by a person skilled in the art, and is 0.0001 to 50 doses per day. It can be administered at mg/kg or 0.001 to 50 mg/kg. Administration may be administered once a day, or may be administered several times. The above dosage does not limit the scope of the present invention in any way. The pharmaceutical composition according to the present invention can be formulated into pills, dragees, capsules, solutions, gels, syrups, slurries, and suspensions.
본 발명의 다른 구현예에 따르면, 본 발명에 따른 상기 균주 조성물을 유효량으로 개체에 투여하는 단계를 포함하는, 알코올성 간질환의 진단, 예방 또는 치료 방법에 관한 것이다.According to another embodiment of the present invention, it relates to a method for diagnosing, preventing, or treating alcoholic liver disease, comprising administering an effective amount of the strain composition according to the present invention to an individual.
본 발명에서 상기 “개체”란, 알코올성 간질환의 예방 또는 치료가 필요한 개체로서, 포유동물 및 비-포유동물을 모두 포함할 수 있다. 여기서, 상기 포유동물의 예로는 인간, 비-인간 영장류, 예컨대 침팬지, 다른 유인원 또는 원숭이 종; 축산 동물, 예컨대 소, 말, 양, 염소, 돼지; 사육 동물, 예컨대 토끼, 개 또는 고양이; 실험 동물, 예를 들어 설치류, 예컨대 랫드, 마우스 또는 기니 피그 등을 포함할 수 있으나, 이에 제한되는 것은 아니다. 또한, 본 발명에서 상기 비-포유동물의 예로는 조류 또는 어류 등을 포함할 수 있으나, 이에 제한되는 것은 아니다. In the present invention, the “individual” refers to an individual in need of prevention or treatment of alcoholic liver disease, and may include both mammals and non-mammals. Here, examples of such mammals include humans, non-human primates, such as chimpanzees, other apes or monkey species; Livestock animals such as cattle, horses, sheep, goats, and pigs; Domesticated animals such as rabbits, dogs or cats; Laboratory animals may include, but are not limited to, rodents such as rats, mice, or guinea pigs. Additionally, examples of the non-mammals in the present invention may include birds or fish, but are not limited thereto.
본 발명에서 용어 “투여”란, 임의의 적절한 방법으로 개체에게 본 발명의 유효성분을 도입하는 과정을 의미하는 것으로서, 본 발명의 상기 치료 방법에서 투여 방법은 경구 또는 비경구 등의 다양한 경로를 통해 투여될 수 있다.In the present invention, the term “administration” refers to the process of introducing the active ingredient of the present invention into an individual by any appropriate method. In the treatment method of the present invention, the administration method is through various routes such as oral or parenteral. may be administered.
본 발명의 목적상, 목적하는 개체에 대한 구체적인 약학적 유효량은 달성하고자 하는 반응의 종류와 정도, 경우에 따라 다른 제제가 사용되는지의 여부를 비롯한 구체적 상기 유효성분을 포함하는 조성물, 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 상기 유효성분을 포함하는 조성물의 분비율, 치료기간, 구체적 조성물과 함께 사용되거나 동시 사용되는 약물을 비롯한 다양한 인자와 의약 분야에 잘 알려진 유사 인자에 따라 다르게 적용하는 것이 바람직하다.
For the purpose of the present invention, the specific pharmaceutically effective amount for the subject of interest is the type and degree of response to be achieved, the composition containing the active ingredient, the patient's age, and whether other agents are used as the case may be. Various factors well known in the medical field, including body weight, general health condition, gender and diet, administration time, administration route and secretion rate of the composition containing the active ingredient, treatment period, and drugs used together or simultaneously with the specific composition. It is desirable to apply it differently depending on similar factors.
본 발명의 또 다른 구현예에 따르면, 수탁번호 KCTC 13670BP인 락토바실러스 헬베티커스 CKDB001 균주를 유효성분으로 포함하는 알코올성 간 기능 개선용 식품 조성물을 제공하는 것일 수 있다.According to another embodiment of the present invention, a food composition for improving alcoholic liver function containing the Lactobacillus helveticus CKDB001 strain, accession number KCTC 13670BP, as an active ingredient may be provided.
본 발명에서, 생략된 나머지 기재들은 본 발명의 나머지 기재와 마찬가지로 해석될 수 있다.
In the present invention, the remaining descriptions omitted may be interpreted similarly to the remaining descriptions of the present invention.
본 발명의 또 다른 구현예에 따르면, 수탁번호 KCTC 13670BP인 락토바실러스 헬베티커스 CKDB001 균주를 유효성분으로 포함하는 숙취해소용 조성물을 제공하는 것일 수 있다.According to another embodiment of the present invention, a composition for relieving a hangover containing the Lactobacillus helveticus CKDB001 strain, accession number KCTC 13670BP, as an active ingredient may be provided.
본 발명에서, 생략된 나머지 기재들은 본 발명의 나머지 기재와 마찬가지로 해석될 수 있다.
In the present invention, the remaining descriptions omitted may be interpreted similarly to the remaining descriptions of the present invention.
본 발명에서, 상기 식품 또는 숙취해소용 조성물은 건강기능식품, 건강식품 또는 식품 첨가제 일 수 있고, 종류에는 특별한 제한은 없다. 일 예로는 드링크제, 육류, 소시지, 빵, 비스킷, 떡, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알코올 음료 및 비타민 복합제, 유제품 및 유가공 제품 등이 있으며, 정제, 캡슐, 환제 또는 액제 형태 등 통상적인 의미에서의 건강기능식품 및 건강식품 조성물을 모두 포함한다.In the present invention, the food or composition for relieving hangovers may be a health functional food, a health food, or a food additive, and there is no particular limitation on the type. Examples include drinks, meat, sausages, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, alcoholic beverages and vitamin complexes, It includes dairy products and milk-processed products, and includes all health functional foods and health food compositions in the conventional sense, such as tablets, capsules, pills, or liquid forms.
본 발명에 따른 상기 균주를 포함하는 건강기능식품, 건강식품 및 식품 첨가제 조성물은 식품 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The health functional food, health food, and food additive composition containing the strain according to the present invention can be added to food as is or used together with other foods or food ingredients, and can be used appropriately according to conventional methods.
본 발명에서, 상기 건강기능식품, 건강식품 또는 식품 첨가제 중의 상기 조성물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 유지를 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양의 범위 이하일 수 있다. In the present invention, the amount of the composition in the health functional food, health food or food additive may be 0.1 to 90 parts by weight of the total weight of the food. However, in the case of long-term intake for the purpose of maintaining health or controlling health, the amount may be below the above range.
본 발명에서 상기 균주를 함유하는 것 외에 추가되는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트라이톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제인 타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강기능식품, 건강식품 또는 식품 첨가제 조성물 100g 당 일반적으로 약 1g 내지 20g, 바람직하게는 약 5g 내지 12g일 수 있다.In the present invention, there is no particular limitation on other ingredients added in addition to containing the above-mentioned strain, and various flavoring agents or natural carbohydrates can be contained as additional ingredients like ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents such as thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate may be generally about 1g to 20g, preferably about 5g to 12g, per 100g of the health functional food, health food or food additive composition of the present invention.
본 발명에서, 상기 균주를 함유하는 건강기능식품, 건강식품 또는 식품 첨가제 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강기능식품 및 건강식품 조성물은 천연 과일쥬스 및 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.
In the present invention, the health functional food, health food or food additive composition containing the above strain contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, Chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the health functional food and health food composition of the present invention may contain pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks.
본 발명의 또 다른 구현예에 따라, 수탁번호 KCTC 13670BP인 락토바실러스 헬베티커스 CKDB001 균주를 유효성분으로 포함하는 간질환의 예방 또는 개선용 사료 조성물이 제공될 수 있다. 상기 사료 조성물은 동물에게 식이를 급여하기 위한 사료 또는 사료 첨가제를 포함하는 것일 수 있다.According to another embodiment of the present invention, a feed composition for preventing or improving liver disease containing the Lactobacillus helveticus CKDB001 strain, accession number KCTC 13670BP, as an active ingredient can be provided. The feed composition may include feed or feed additives for feeding animals.
본 발명의 상기 락토바실러스 헬베티커스 CKDB001 균주가 사료 조성물 또는 사료 첨가제 조성물에 함유되어 이용될 경우, 상기 조성물은 20 내지 90% 고농축액이거나 분말 또는 과립형태로 제조될 수 있다. 상기 사료 첨가제는 구연산, 후말산, 아디픽산, 젖산, 사과산 등의 유기산이나 인산나트륨, 인산칼륨, 산성 피로인산염 등의 인산염이나, 폴리페놀, 카테킨, 알파-토코페롤, 로즈마리 추출물, 비타민 C, 녹차 추출물, 감초 추출물, 키토산, 탄닌산, 피틴산 등의 천연 항산화제 중 어느 하나 또는 하나 이상을 추가로 포함할 수 있다. When the Lactobacillus helveticus CKDB001 strain of the present invention is used in a feed composition or a feed additive composition, the composition may be a 20 to 90% highly concentrated solution or may be prepared in the form of powder or granules. The feed additives include organic acids such as citric acid, malic acid, adipic acid, lactic acid, and malic acid, phosphates such as sodium phosphate, potassium phosphate, and acid pyrophosphate, polyphenols, catechin, alpha-tocopherol, rosemary extract, vitamin C, and green tea extract. , licorice extract, chitosan, tannic acid, phytic acid, etc., may additionally contain one or more of natural antioxidants.
본 발명에서, 상기 균주가 사료로 이용될 경우, 상기 조성물은 통상의 사료 형태로 제제화될 수 있으며, 통상의 사료 성분을 함께 포함할 수 있다. 상기 사료 첨가제 및 사료는 곡물, 예를 들면 분쇄 또는 파쇄된 밀, 귀리, 보리, 옥수수 및 쌀; 식물성 단백질 사료, 예를 들면 평지, 콩 및 해바라기를 주성분으로 하는 사료; 동물성 단백질 사료, 예를 들면 혈분, 육분, 골분 및 생선분; 당분 및 유제품, 예를 들면 각종 분유 및 유장 분말로 이루어지는 건조 성분 등을 더 포함할 수 있으며, 이외에도 영양 보충제, 소화 및 흡수 향상제, 성장 촉진제 등을 더 포함할 수 있다. In the present invention, when the strain is used as feed, the composition may be formulated in the form of a normal feed and may include common feed ingredients. The feed additives and feeds include grains such as ground or crushed wheat, oats, barley, corn and rice; Vegetable protein feeds, such as those based on rape, soybean and sunflower; Animal protein feeds such as blood meal, meat meal, bone meal and fish meal; It may further include dry ingredients such as sugar and dairy products, such as various powdered milk and whey powder, and may further include nutritional supplements, digestion and absorption enhancers, growth promoters, etc.
본 발명에서, 상기 균주가 상기 사료 첨가제로 사용될 경우에는 동물에게 단독으로 투여하거나 식용 담체 중에서 다른 사료 첨가제와 조합하여 투여할 수도 있다. 또한, 상기 사료 첨가제는 탑 드레싱으로서 또는 이들을 동물 사료에 직접 혼합하거나 또는 사료와 별도의 경구 제형으로 용이하게 동물에게 투여할 수 있다. 상기 사료 첨가제를 동물 사료와 별도로 투여할 경우, 당해 기술분야에 잘 알려진 바와 같이 약제학적으로 허용 가능한 식용 담체와 조합하여, 즉시 방출 또는 서방성 제형으로 제조할 수 있다. 이러한 식용 담체는 고체 또는 액체, 예를 들어 옥수수 전분, 락토오스, 수크로오스, 콩 플레이크, 땅콩유, 올리브유, 참깨유 및 프로필렌글리콜일 수 있다. 고체 담체가 사용될 경우, 사료 첨가제는 정제, 캡슐제, 산제, 트로키제 또는 함당정제 또는 미분산성 형태의 탑 드레싱일 수 있다. 액체 담체가 사용될 경우, 사료 첨가제는 젤라틴 연질 캡슐제, 또는 시럽제나 현탁액, 에멀젼제, 또는 용액제의 제형일 수 있다. 상기 사료는 동물의 식이 욕구를 충족시키는데 통상적으로 사용되는 임의의 단백질-함유 유기 곡분을 포함할 수 있다. 이러한 단백질-함유 곡분은 통상적으로 옥수수, 콩 곡분, 또는 옥수수/콩 곡분 믹스로 구성되어 있다. 또한 사료 조성물은 예를 들어 보존제, 안정화제, 습윤제 또는 유화제, 용액 촉진제 등을 함유할 수 있다. 또한 사료 첨가제 조성물은 침지, 분무 또는 혼합하여 동물의 사료에 첨가하여 이용될 수 있다.In the present invention, when the strain is used as the feed additive, it can be administered to animals alone or in combination with other feed additives in an edible carrier. Additionally, the feed additives can be easily administered to animals as a top dressing, by mixing them directly into animal feed, or in an oral formulation separate from the feed. When the feed additive is administered separately from animal feed, it can be prepared into an immediate-release or sustained-release formulation by combining it with a pharmaceutically acceptable edible carrier, as is well known in the art. These edible carriers can be solid or liquid, such as corn starch, lactose, sucrose, soybean flakes, peanut oil, olive oil, sesame oil and propylene glycol. If a solid carrier is used, the feed additive may be a tablet, capsule, powder, troche or sugar-containing tablet or a top dressing in microdisperse form. If a liquid carrier is used, the feed additive may be in the form of gelatin soft capsules, or in the form of syrup, suspension, emulsion, or solution. The feed may include any protein-containing organic cereal flour commonly used to meet the dietary needs of animals. These protein-containing flours typically consist of corn, soybean flour, or corn/soybean flour mix. Additionally, the feed composition may contain, for example, preservatives, stabilizers, wetting or emulsifying agents, solution accelerators, etc. Additionally, the feed additive composition can be used by adding it to animal feed by dipping, spraying, or mixing.
본 발명의 사료 또는 사료 첨가제 급여의 대상은 알코올성 간질환의 예방 또는 개선이 필요한 개체로, 상기 개체는 상기 염증성 질환이 발생하였거나 발생할 수 있는 인간을 제외한 모든 동물을 포함할 수 있고, 상기 동물은 비-인간 영장류, 예컨대 침팬지, 다른 유인원 또는 원숭이 종; 축산 동물, 예컨대 소, 말, 양, 염소, 돼지; 사육 동물, 예컨대 토끼, 개 또는 고양이; 실험 동물, 예를 들어 설치류, 예컨대 랫드, 마우스 또는 기니 피그; 비-포유동물, 예를 들어 조류 또는 어류 등을 포함할 수 있으나, 이에 제한되는 것은 아니다.The subject of feeding the feed or feed additive of the present invention is an entity in need of prevention or improvement of alcoholic liver disease. The entity may include all animals other than humans that have developed or may develop the inflammatory disease, and the animals include non-humans. -human primates, such as chimpanzees, other apes or monkey species; Livestock animals such as cattle, horses, sheep, goats, and pigs; Domesticated animals such as rabbits, dogs or cats; Laboratory animals, for example rodents such as rats, mice or guinea pigs; Non-mammals, such as birds or fish, may be included, but are not limited thereto.
본 발명에서, 생략된 나머지 기재들은 앞서 기재된 조성물의 기재와 마찬가지로 해석될 수 있다.
In the present invention, the remaining omitted descriptions can be interpreted similarly to the description of the composition described above.
이하 본 발명을 실시예에 의하여 더욱 상세하게 설명한다. 이들 실시예는 단지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited to these examples.
실시예 1. Example 1. L. helveticusL. helveticus CKDB001 조성물의 준비 Preparation of CKDB001 composition
L. helveticus CKDB001 균주는 ㈜종근당바이오에서 공급받았다. L. helveticus CKDB001 균주는 동결건조 시킨 미세분말 형태로 전달받았다. L. helveticus CKDB001 균주는 1x109 CFU/g의 농도로 증류수에 현탁 하여 주 2회 공급하였다.
L. helveticus CKDB001 strain was supplied by Chong Kun Dang Bio Co., Ltd. The L. helveticus CKDB001 strain was delivered in the form of freeze-dried fine powder. The L. helveticus CKDB001 strain was suspended in distilled water at a concentration of 1x10 9 CFU/g and supplied twice a week.
실시예 2. 알코올성 간질환 유도 마우스 모델 수립Example 2. Establishment of alcoholic liver disease-induced mouse model
동물모델 평가를 위하여 알코올성 간질환 유도 마우스 모델을 유도하였고, 샘플을 수집하였다. 실험동물은 인도주의적 치료를 받았다. 또한 모든 절차는 실험실 동물의 관리 및 사용을 위한 국립보건원 지침을 따랐으며 한림대학교 의과대학 동물실험 및 위원회의 승인을 받았다. To evaluate the animal model, an alcoholic liver disease-induced mouse model was derived and samples were collected. Experimental animals received humane treatment. Additionally, all procedures followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of Hallym University College of Medicine.
먼저 특정 병원체가 없는 7주령의 C57BL/6J 수컷 마우스를 두열바이오텍 (서울, 한국)에서 구매하였다. 모든 마우스들은 12/12시간 명/암 주기로 22±2℃온도에서 전용 케이지에 개별적으로 수용되었다. 또한 실험 진행 동안 모든 마우스들은 물과 음식에 자유롭게 접근할 수 있도록 하였다. 실험은 모든 그룹에 대한 적응기간을 포함하였고, 이 기간 동안에는 1주일 동안 정상적인 사료를 제공하였다.First, 7-week-old C57BL/6J male mice without specific pathogens were purchased from Duyeol Biotech (Seoul, Korea). All mice were individually housed in dedicated cages at a temperature of 22 ± 2°C with a 12/12 hour light/dark cycle. Additionally, all mice had free access to water and food during the experiment. The experiment included an adaptation period for all groups, during which normal food was provided for one week.
식이 섭취로 알코올성 간질환 모델을 유도하기 위해 에탄올 포함 식이를 제조하여 10주간 자유롭게 섭취하도록 하였다. 알코올성 간질환 모델 마우스는 정상대조군(NC, n=10), 알코올성 간질환 유도 식이군(EtOH-fed, n=10), 그리고 알코올성 간질환 유도 식이와 함께 L. helveticus CKDB001 균주 섭취군(EtOH+LH, n=10)으로 분류하였다(도 1).To induce an alcoholic liver disease model through dietary intake, a diet containing ethanol was prepared and allowed to consume freely for 10 weeks. The alcoholic liver disease model mice were a normal control group (NC, n=10), an alcoholic liver disease inducing diet group (EtOH-fed, n=10), and a group ingesting the L. helveticus CKDB001 strain along with the alcoholic liver disease inducing diet group (EtOH+ LH, n=10) (Figure 1).
실험 시작 12주 후, 상기 마우스에 흡입 마취제 (에어래인액, 미국)를 투여하여 희생시켰다. 다음으로, 체중과 간 무게를 측정하고 혈액 및 간 조직을 분리하였고, 전혈 샘플을 원심 분리 (2,000 g, 20분)하여 혈청을 분리하였다. 간 조직은 빠르게 분리하여 -80℃에 보관하였다.
12 weeks after the start of the experiment, the mice were sacrificed by administering an inhalation anesthetic (Airlane Solution, USA). Next, body weight and liver weight were measured, blood and liver tissue were separated, and the whole blood sample was centrifuged (2,000 g, 20 minutes) to separate serum. Liver tissue was quickly separated and stored at -80°C.
실시예 3. 데이터 분석Example 3. Data analysis
연속 변수는 평균 및 표준편차로 분석하였다. 조직학 분석과 간 기능 분석 및 분류학적 바이오마커 발견을 위해 One-way ANOVA을 수행하였다. 유의확률 P값 <0.05는 통계적 유의성을 나타내는 것으로 간주하였다. 모든 통계 분석은 GraphPad Prism (ver. 8.0.2, GraphPad Software, LLC, San Diego, CA 92108 USA)를 사용하여 수행하였다.
Continuous variables were analyzed by mean and standard deviation. One-way ANOVA was performed for histological analysis, liver function analysis, and taxonomic biomarker discovery. A significance probability P value of <0.05 was considered to indicate statistical significance. All statistical analyzes were performed using GraphPad Prism (ver. 8.0.2, GraphPad Software, LLC, San Diego, CA 92108 USA).
실시예 4. 간 조직의 병리학적 분석Example 4. Pathological analysis of liver tissue
분리된 간 조직을 10% 포르말린으로 고정시키고 파라핀으로 블록을 제작하였고, 조직 섹션에 대하여 헤마톡실린에오신 (H&E) 염색을 하였다. 알코올성 간질환의 병리학적 분석은 지방증 (Fatty change), 지방증에 의한 실질 조직 침범 정도 평가 [등급0: <5%, 1: 5~33%, 2: >33~66%, 3: >66%], 염증 (Grade), 모든 염증 병소 (foci)의 전반적 평가[등급0: <No foci, 1: <2 foci per 200x field, 2: 2~4 foci per 200x field, 3: >4 foci per 200x field], 간의 손상 단계 (Stage), 손상이 발생한 세포 비율 [등급0: None, 1: Inflammation, 2: Fibrosis, 3: Cirrhosis]로 수행하였다. The isolated liver tissue was fixed with 10% formalin, paraffin blocks were made, and the tissue sections were stained with hematoxylin eosin (H&E). Pathological analysis of alcoholic liver disease evaluates steatosis (Fatty change) and the degree of parenchymal invasion by steatosis [Grade 0: <5%, 1: 5~33%, 2: >33~66%, 3: >66% ], Inflammation (Grade), overall evaluation of all inflammatory foci [Grade 0: <No foci, 1: <2 foci per 200x field, 2: 2~4 foci per 200x field, 3: >4 foci per 200x field], liver damage stage (Stage), and proportion of damaged cells [Grade 0: None, 1: Inflammation, 2: Fibrosis, 3: Cirrhosis].
위와 같이 제시된 병리학적 분석법에 따라 정상식이를 섭취한 정상대조군에 비해 에탄올 포함 식이를 섭취한 군에서 지방증, 염증 및 간의 손상이 발생하였고, L. helveticus CKDB001 균주 섭취에 의해 지방증, 염증 및 간의 손상이 감소하였다 (도 2). [Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.]
According to the pathological analysis method presented above, steatosis, inflammation, and liver damage occurred in the group that consumed a diet containing ethanol compared to the normal control group that consumed a normal diet, and steatosis, inflammation, and liver damage occurred due to ingestion of L. helveticus CKDB001 strain. decreased (Figure 2). [Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.]
실시예 5. 간 기능 지표 측정 및 분석Example 5. Measurement and analysis of liver function indicators
분리한 혈청으로 aspartate aminotransferase (AST), alanine aminotransferase (ALT)를 혈액생화학분석기 (KoneLab 20, Thermo Fisher Scientific, Waltham, Finland)를 이용하여 측정하였다. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured in the separated serum using a blood biochemistry analyzer (KoneLab 20, Thermo Fisher Scientific, Waltham, Finland).
그 결과 정상 대조군을 나타내는 normal control (NC)군에 비해 에탄올 포함 식이를 섭취한 질병 유도군 (EtOH-fed)에서 간 기능 지표인자인 AST와 ALT의 수치가 증가하였고 에탄올 포함 식이를 섭취한 질병 유도군에 비해 L. helveticus CKDB001 균주를 처리한 군 (EtOH+LH)에서는 AST와 ALT의 값이 유의적으로 감소하였다. L. helveticus CKDB001 균주는 에탄올 포함 식이에 의해 유도된 알코올성 간질환을 효과적으로 개선하는 결과를 보였다. 상기 결과로부터 L. helveticus CKDB001 균주가 에탄올 포함 식이 섭취로 유도되는 알코올성 간질환을 개선하는데 유용한 소재임을 알 수 있다 (도 3).
As a result, compared to the normal control (NC) group, which represents the normal control group, the levels of AST and ALT, which are indicators of liver function, increased in the disease-induced group (EtOH-fed) that consumed an ethanol-containing diet, and the disease-induced group that consumed an ethanol-containing diet Compared to the group treated with the L. helveticus CKDB001 strain (EtOH+LH), the values of AST and ALT were significantly decreased. The L. helveticus CKDB001 strain showed effective improvement in alcoholic liver disease induced by an ethanol-containing diet. From the above results, it can be seen that the L. helveticus CKDB001 strain is a useful material for improving alcoholic liver disease induced by dietary intake containing ethanol (FIG. 3).
실시예 6. 간 염증 지표 측정 및 분석Example 6. Measurement and analysis of liver inflammation indicators
간 조직에서 total RNA의 분리는 제조사의 지시에 따라 트리졸 시약 키트 (인비트로젠, 미국)를 사용하여 수행했다. cDNA 합성 키트 (어플라이드 바이오시스템즈, 미국)를 사용하여 total RNA (2 μg)를 cDNA로 합성했다. cDNA는 루나 유니버셜 마스터 믹스 (뉴잉글랜드바이오랩, 미국) 및 각 표적-특이적 프로브-프라이머를 사용하여 정량적 PCR (qPCR)을 수행하였다. Isolation of total RNA from liver tissue was performed using the Trizol reagent kit (Invitrogen, USA) according to the manufacturer's instructions. Total RNA (2 μg) was synthesized into cDNA using a cDNA synthesis kit (Applied Biosystems, USA). cDNA was subjected to quantitative PCR (qPCR) using Luna Universal Master Mix (New England Biolab, USA) and each target-specific probe-primer.
L. helveticus CKDB001 균주가 면역 기전에 미치는 영향을 알아보기 위해 염증성 사이토카인 및 케모카인 유전자인 Tnf-α, Il-1β, Cxcl2, Cxcl9, Ly6g, E-selectin의 mRNA level을 분석하였다. 에탄올 포함 식이로 인해 증가한 Tnf-α, Il-1β, Cxcl2, Cxcl9, Ly6g, E-selectin의 유전자 발현이 L. helveticus CKDB001 균주에 의해 줄어들었다.To determine the effect of L. helveticus CKDB001 strain on immune mechanisms, the mRNA levels of inflammatory cytokine and chemokine genes Tnf-α, Il-1β, Cxcl2, Cxcl9, Ly6g, and E-selectin were analyzed. Gene expression of Tnf-α, Il-1β, Cxcl2, Cxcl9, Ly6g, and E-selectin, which increased due to ethanol-containing diet, was decreased by L. helveticus CKDB001 strain.
이 결과로 L. helveticus CKDB001 균주가 에탄올 포함 식이 섭취로 인해 유도되는 염증 발생을 개선하는 소재임을 알 수 있었다 (도 4).
These results showed that the L. helveticus CKDB001 strain was a material that improved the occurrence of inflammation induced by ingestion of a diet containing ethanol (Figure 4).
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시예일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.
As the specific parts of the present invention have been described in detail above, it is clear to those skilled in the art that these specific techniques are merely preferred embodiments and do not limit the scope of the present invention. will be. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (8)
상기 균주는 알코올에 의해 증가된 Tnf-α, Cxcl2, Cxcl9, Ly6g, E-selectin의 발현 수준을 감소시키는, 알코올성 간질환의 예방 또는 치료용 약학적 조성물.
Contains Lactobacillus Helveticus CKDB001 strain with accession number KCTC 13670BP as an active ingredient,
The strain is a pharmaceutical composition for preventing or treating alcoholic liver disease, which reduces the expression level of Tnf-α, Cxcl2, Cxcl9, Ly6g, and E-selectin increased by alcohol.
상기 균주는 1x108 CFU/g 이상 농도인 것인, 약학적 조성물.
According to paragraph 1,
A pharmaceutical composition wherein the strain has a concentration of 1x10 8 CFU/g or more.
상기 균주는 알코올에 의해 증가된 Tnf-α, Cxcl2, Cxcl9, Ly6g, E-selectin의 발현 수준을 감소시키는, 알코올성 간 질환의 개선용 식품 조성물.
Contains Lactobacillus Helveticus CKDB001 strain with accession number KCTC 13670BP as an active ingredient,
The strain is a food composition for improving alcoholic liver disease, which reduces the expression level of Tnf-α, Cxcl2, Cxcl9, Ly6g, and E-selectin increased by alcohol.
상기 균주는 1x108 CFU/g 이상 농도인 것인, 식품 조성물.
According to clause 5,
The food composition wherein the strain has a concentration of 1x10 8 CFU/g or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220053421A KR102626672B1 (en) | 2022-04-29 | 2022-04-29 | Composition comprising a Lactobacillus helveticus CKDB001 strain for the prevention, improvement, or treatment of alcoholic liver disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220053421A KR102626672B1 (en) | 2022-04-29 | 2022-04-29 | Composition comprising a Lactobacillus helveticus CKDB001 strain for the prevention, improvement, or treatment of alcoholic liver disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230153702A KR20230153702A (en) | 2023-11-07 |
| KR102626672B1 true KR102626672B1 (en) | 2024-01-18 |
Family
ID=88747372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220053421A KR102626672B1 (en) | 2022-04-29 | 2022-04-29 | Composition comprising a Lactobacillus helveticus CKDB001 strain for the prevention, improvement, or treatment of alcoholic liver disease |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102626672B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102038695B1 (en) | 2018-10-30 | 2019-10-30 | 주식회사 종근당바이오 | Composition for Preventing or Treating Alcoholic Intestinal Damage Comprising Probiotics as Effective Ingredients |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102279283B1 (en) * | 2019-10-14 | 2021-07-20 | 주식회사 종근당바이오 | Composition for preventing, alleviating, or treating NAFLD comprising Lactobacillus helveticus and Bifidobacterium species |
-
2022
- 2022-04-29 KR KR1020220053421A patent/KR102626672B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102038695B1 (en) | 2018-10-30 | 2019-10-30 | 주식회사 종근당바이오 | Composition for Preventing or Treating Alcoholic Intestinal Damage Comprising Probiotics as Effective Ingredients |
Non-Patent Citations (1)
| Title |
|---|
| 석기태 등, 장내 마이크로바이옴 연구에 기반한 만성간질환 치료용 파마바이오틱스 개발, 과학기술정보통신부 최종보고서, 한림대학교, 과제번호 2018M3A9F3020942, 2021.* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230153702A (en) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102032982B1 (en) | Composition for preventing, improving or treating obesity or fatty liver disease comprising the Leuconostoc citreum WiKim0104 | |
| KR102123505B1 (en) | Lactobacillus sakei WIKIM0109 having anti-arthritis activity and composition for comprising the same | |
| KR102072059B1 (en) | Composition for preventing, improving or treating obesity or fatty liver disease comprising the Weissella hellenica WiKim0103 | |
| KR20190051771A (en) | Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same | |
| US20210268038A1 (en) | Composition for improving intestinal function comprising leuconostoc sp. strain | |
| KR101834383B1 (en) | Weissella cibaria WIKIM28 having anti-obesity activity and composition for comprising the same | |
| AU2019416609B2 (en) | Kimchi for preventing or treating helicobacter pylori-associated diseases | |
| KR102626672B1 (en) | Composition comprising a Lactobacillus helveticus CKDB001 strain for the prevention, improvement, or treatment of alcoholic liver disease | |
| KR101838280B1 (en) | Leuconostoc citreum WIKIM56 having anti-arthritis activity and composition for comprising the same | |
| KR101834379B1 (en) | Weissella confusa WIKIM51 having anti-obesity activity and composition for comprising the same | |
| KR102571732B1 (en) | Composition comprising a Pediococcus pentosaceus KID7 strain for the prevention, improvement, or treatment of alcoholic liver disease | |
| KR102133473B1 (en) | A composition as a prebiotic for improving intestinal microflora containing sweet potato vines | |
| KR20230148538A (en) | Composition comprising Phocaeicola dorei strain and Lactobacillus acidophilus strain | |
| RU2793287C2 (en) | Kimchi for the prevention or treatment of helicobacterpylori-related diseases | |
| KR20230001030A (en) | Composition for preventing and treating liver disease comprising Bacteroides dorei | |
| KR102546973B1 (en) | Composition for enhancing immunity comprising Bacillus velenzensis Kh2-2 | |
| JP7398714B2 (en) | Akkermansia muciniphila proliferation-promoting composition applicable to medical and beauty treatments, as well as pharmaceuticals, food and beverages, and feed containing the same | |
| KR102593538B1 (en) | Pharmaceutical composition for preventing or treating liver fibrosis comprising Bacteroides dorei train | |
| KR101081460B1 (en) | Composition comprising Leuconostoc mesenteroides Ｅ―１ of having anti―allergy, anti―inflammatory and anti―asthma activity | |
| US11497779B2 (en) | Growth-stimulating Lactobacillus strains | |
| KR20220023301A (en) | Composition for treating brain diseases comprising lactobacillus sakei or extracellular vesicle derived therefrom as an active ingredient | |
| KR20240005616A (en) | A pharmaceutical composition for preventing or treating liver fibrosis containing Lactobacillus delbrueckii subsp. lactis CKDB001 | |
| EP3837993A1 (en) | Composition for improving intestinal function comprising leuconostoc sp. strain | |
| JP2024506051A (en) | Pharmaceutical composition for preventing or treating intestinal damage containing Leuconostoc citreum strain as an active ingredient | |
| TW202335676A (en) | Intestine immunostimulant and IgA generation promoter for ensuring Apilactobacillus lactobacillus having IgA generation promotion effect and immunostimulation function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |